Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1999 Jan 26;160(2):225–232.

Prostate cancer: 9. Treatment of advanced disease

M E Gleave 1, N Bruchovsky 1, M J Moore 1, P Venner 1
PMCID: PMC1229995  PMID: 9951446

Abstract

A 70-year-old man is referred to a urologist for recommendations on the management of metastatic prostate cancer. His cancer was diagnosed 5 years ago, and he underwent radical prostatectomy at that time. The tumour was confined to the prostate gland (Gleason score 7), and during surgery the lymph nodes were assessed as being clear of cancer. Before the surgery, the patient's prostate-specific antigen (PSA) level had been 8 ng/mL. After the prostatectomy, PSA was at first undetectable, but recently the PSA level rose to 2 ng/mL and then, at the most recent test, to 16 ng/mL. A bone scan was ordered to investigate back discomfort, which has been persistent but easily controlled with acetaminophen. Unfortunately, the bone scan shows several sites of metastatic disease. The man's medical history includes type 2 diabetes, which has developed during the past 3 years and which is controlled by diet, as well as asymptomatic hypertension, which is managed by means of a thiazide diuretic. The patient asks what treatments are available, what impact they are likely to have on his disease and what risks are associated with the therapies.

Full Text

The Full Text of this article is available as a PDF (140.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blackledge G. R. High-dose bicalutamide monotherapy for the treatment of prostate cancer. Urology. 1996 Jan;47(1A):44–53. doi: 10.1016/s0090-4295(96)80008-2. [DOI] [PubMed] [Google Scholar]
  2. Bolla M., Gonzalez D., Warde P., Dubois J. B., Mirimanoff R. O., Storme G., Bernier J., Kuten A., Sternberg C., Gil T. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997 Jul 31;337(5):295–300. doi: 10.1056/NEJM199707313370502. [DOI] [PubMed] [Google Scholar]
  3. Bruchovsky N., Goldenberg S. L., Akakura K., Rennie P. S. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol. Cancer. 1993 Sep 1;72(5):1685–1691. doi: 10.1002/1097-0142(19930901)72:5<1685::aid-cncr2820720532>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  4. Bruchovsky N., Wilson J. D. The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem. 1968 Apr 25;243(8):2012–2021. [PubMed] [Google Scholar]
  5. Byar D. P. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer. 1973 Nov;32(5):1126–1130. doi: 10.1002/1097-0142(197311)32:5<1126::aid-cncr2820320518>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  6. Cox R. L., Crawford E. D. Estrogens in the treatment of prostate cancer. J Urol. 1995 Dec;154(6):1991–1998. [PubMed] [Google Scholar]
  7. Crawford E. D., Eisenberger M. A., McLeod D. G., Spaulding J. T., Benson R., Dorr F. A., Blumenstein B. A., Davis M. A., Goodman P. J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989 Aug 17;321(7):419–424. doi: 10.1056/NEJM198908173210702. [DOI] [PubMed] [Google Scholar]
  8. Eisenberger M. A., Reyno L. M., Jodrell D. I., Sinibaldi V. J., Tkaczuk K. H., Sridhara R., Zuhowski E. G., Lowitt M. H., Jacobs S. C., Egorin M. J. Suramin, an active drug for prostate cancer: interim observations in a phase I trial. J Natl Cancer Inst. 1993 Apr 21;85(8):611–621. doi: 10.1093/jnci/85.8.611. [DOI] [PubMed] [Google Scholar]
  9. Fleshner N. E., Trachtenberg J. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urol. 1995 Nov;154(5):1642–1646. [PubMed] [Google Scholar]
  10. Gleave M., Bruchovsky N., Goldenberg S. L., Rennie P. Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Eur Urol. 1998;34 (Suppl 3):37–41. doi: 10.1159/000052297. [DOI] [PubMed] [Google Scholar]
  11. Goldenberg S. L., Bruchovsky N., Gleave M. E., Sullivan L. D. Low-dose cyproterone acetate plus mini-dose diethylstilbestrol--a protocol for reversible medical castration. Urology. 1996 Jun;47(6):882–884. doi: 10.1016/S0090-4295(96)00048-9. [DOI] [PubMed] [Google Scholar]
  12. Hudes G. R., Greenberg R., Krigel R. L., Fox S., Scher R., Litwin S., Watts P., Speicher L., Tew K., Comis R. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol. 1992 Nov;10(11):1754–1761. doi: 10.1200/JCO.1992.10.11.1754. [DOI] [PubMed] [Google Scholar]
  13. Hudes G. R., Nathan F., Khater C., Haas N., Cornfield M., Giantonio B., Greenberg R., Gomella L., Litwin S., Ross E. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1997 Sep;15(9):3156–3163. doi: 10.1200/JCO.1997.15.9.3156. [DOI] [PubMed] [Google Scholar]
  14. Huggins C., Scott W. W. Bilateral Adrenalectomy in Prostatic Cancer: Clinical Features and Urinary Excretion of 17-Ketosteroids and Estrogen. Ann Surg. 1945 Dec;122(6):1031–1041. [PMC free article] [PubMed] [Google Scholar]
  15. Kelly W. K., Curley T., Leibretz C., Dnistrian A., Schwartz M., Scher H. I. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol. 1995 Sep;13(9):2208–2213. doi: 10.1200/JCO.1995.13.9.2208. [DOI] [PubMed] [Google Scholar]
  16. Miller J. I., Ahmann F. R., Drach G. W., Emerson S. S., Bottaccini M. R. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol. 1992 Mar;147(3 Pt 2):956–961. doi: 10.1016/s0022-5347(17)37432-3. [DOI] [PubMed] [Google Scholar]
  17. Moore M. J., Osoba D., Murphy K., Tannock I. F., Armitage A., Findlay B., Coppin C., Neville A., Venner P., Wilson J. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol. 1994 Apr;12(4):689–694. doi: 10.1200/JCO.1994.12.4.689. [DOI] [PubMed] [Google Scholar]
  18. Myers C., Cooper M., Stein C., LaRocca R., Walther M. M., Weiss G., Choyke P., Dawson N., Steinberg S., Uhrich M. M. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol. 1992 Jun;10(6):881–889. doi: 10.1200/JCO.1992.10.6.881. [DOI] [PubMed] [Google Scholar]
  19. Newling D. W., Denis L., Vermeylen K. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853. Cancer. 1993 Dec 15;72(12 Suppl):3793–3798. doi: 10.1002/1097-0142(19931215)72:12+<3793::aid-cncr2820721706>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  20. Pienta K. J., Redman B., Hussain M., Cummings G., Esper P. S., Appel C., Flaherty L. E. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol. 1994 Oct;12(10):2005–2012. doi: 10.1200/JCO.1994.12.10.2005. [DOI] [PubMed] [Google Scholar]
  21. Rennie P. S., Bruchovsky N., Leco K. J., Sheppard P. C., McQueen S. A., Cheng H., Snoek R., Hamel A., Bock M. E., MacDonald B. S. Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Mol Endocrinol. 1993 Jan;7(1):23–36. doi: 10.1210/mend.7.1.8446105. [DOI] [PubMed] [Google Scholar]
  22. Schellhammer P. F., Sharifi R., Block N. L., Soloway M. S., Venner P. M., Patterson A. L., Sarosdy M. F., Vogelzang N. J., Chen Y., Kolvenbag G. J. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. Cancer. 1996 Nov 15;78(10):2164–2169. doi: 10.1002/(sici)1097-0142(19961115)78:10<2164::aid-cncr18>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  23. Schmidt J. D., Scott W. W., Gibbons R., Johnson D. E., Prout G. R., Jr, Loening S., Soloway M., deKernion J. B., Pontes J. E., Slack N. H. Chemotherapy programs of the National Prostatic Cancer Project (NPCP). Cancer. 1980 Apr 15;45(7 Suppl):1937–1946. [PubMed] [Google Scholar]
  24. Tannock I. F., Osoba D., Stockler M. R., Ernst D. S., Neville A. J., Moore M. J., Armitage G. R., Wilson J. J., Venner P. M., Coppin C. M. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996 Jun;14(6):1756–1764. doi: 10.1200/JCO.1996.14.6.1756. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES